BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
BeiGene, Ltd. - American Depositary Shares (BGNE)
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beigene.com/phoenix.zhtml?c=254246&p=irol-irhome_pf
Company Research
Source: Business Wire
Results from RATIONALE-315, 307 and 305 support the benefits of PD-1 inhibitor TEVIMBRA (tislelizumab) in non-small cell lung cancer and gastric cancer/gastroesophageal junction cancer BASEL, Switzerland--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA® (tislelizumab) at the European Society of Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, September 13-17, 2024. BeiGene has seven abstracts accepted at ESMO 2024, with one selected for the special session revisiting the ESMO Virtual Plenary held in February 2024.New Data Add to Evidence for TEVIMBRA Across Multiple Disease StatesAs an encore to the ESMO plenary, interim results from the RATIONALE-315 study show the statistically significant event-free survival (EFS) and trend for overall survival (OS) benefit favoring neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab vs. placebo plus chemothera
Show less
Read more
Impact Snapshot
Event Time:
BGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BGNE alerts
High impacting BeiGene, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BGNE
News
- BeiGene, Ltd. (NASDAQ: BGNE) is now covered by analysts at JMP Securities. They set a "market outperform" rating and a $288.00 price target on the stock.MarketBeat
- BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior ChemotherapyBusiness Wire
- BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk [Yahoo! Finance]Yahoo! Finance
- BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest TalkPR Newswire
- BeiGene Announces Updates to Commercial Leadership TeamBusiness Wire
BGNE
Earnings
- 8/7/24 - Beat
BGNE
Sec Filings
- 9/19/24 - Form 4
- 9/17/24 - Form 144
- 9/5/24 - Form 4
- BGNE's page on the SEC website